Verve Therapeutics, Inc.
VERVDelisted Jul 25, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840574
Verve Therapeutics, Inc. was delisted on Jul 25, 2025; its insiders filed their last Form 4 on Jul 28, 2025; 176 institutions reported holding it in 13F filings for Q2 2025, worth $819.4M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 176
- Q2 2025, −13 vs. previous quarter
- 13F value
- $819.4M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding VERV, Q2 2025
No superinvestor reported holding VERV at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by Verve Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Kathiresan SekarChief Executive Officer | SSale | −9.82K | $4.15 | −$40.8K | −2.8%346.7K after | 10b5-1 |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Nickerson JoanChief Administrative Officer | SSale | −2.78K | $4.15 | −$11.5K | −13.7%17.4K after | 10b5-1 |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Ashe Andrew D.See Remarks | SSale | −2.68K | $4.15 | −$11.1K | −0.8%348.8K after | 10b5-1 |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Politi JasonChief Technical Ops. Off. | SSale | −3.23K | $4.15 | −$13.4K | −18.5%14.2K after | 10b5-1 |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Dorval AllisonChief Financial Officer | SSale | −3.35K | $4.15 | −$13.9K | −20.1%13.3K after | 10b5-1 |
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Lister TroyChief Scientific Officer | SSale | −2.19K | $4.15 | −$9.08K | −23.9%6.95K after | 10b5-1 |
| Dec 3, 2024 (view filing) | Dec 2 | 1 day | Dorval AllisonChief Financial Officer | SSale | −555 | $5.64 | −$3.13K | −9.4%5.38K after | |
| May 15, 2024 (view filing) | May 14 | 1 day | Ashe Andrew D.See Remarks | PPurchase | +76.0K | $6.26 | +$475.8K | +28.5%342.5K after | |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Nickerson JoanChief Administrative Officer | SSale | −1.51K | $8.24 | −$12.5K | −14.9%8.66K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Dec 1 | 4 days | Yeshwant KrishnaDirector, 10% Owner | PPurchase | +1.80M | $10.00 | +$18.0M | New position1.80M after |
Top 10 13F holders, Q2 2025
The largest institutional positions in Verve Therapeutics, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alphabet Inc. | 12,168,489 | $136.7M | 6.40% | −180,597−1.5% | Reduced |
| BlackRock, Inc. | 7,356,721 | $82.6M | 0.00% | −521,515−6.6% | Reduced |
| Pentwater Capital Management LP | 6,720,000 | $75.5M | 0.96% | +6,720,000 | New |
| Vanguard Group Inc | 4,191,854 | $47.1M | 0.00% | +236,755+6.0% | Added |
| Casdin Capital, LLC | 4,095,571 | $46.0M | 4.19% | +100,000+2.5% | Added |
| Farallon Capital Management, L.L.C. | 3,612,000 | $40.6M | 0.18% | +2,700,000+296.1% | Added |
| Alpine Associates Management Inc. | 2,738,212 | $30.8M | 1.65% | +2,738,212 | New |
| State Street Corp | 2,626,859 | $29.5M | 0.00% | −464,330−15.0% | Reduced |
| ARCH Venture Management, LLC | 2,008,809 | $22.6M | 7.54% | 00.0% | Unchanged |
| UBS Group AG | 1,870,522 | $21.0M | 0.00% | +1,738,749+1,319.5% | Added |
Holders of 5% or more of VERV
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Verve Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Pentwater Capital Management LP | 13G | 7.50%6.72M shares | New | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.00%6.18M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |